Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Subscribe To Our Newsletter & Stay Updated
